Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Amgen Inc., profitability ratios (quarterly data)
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Amgen Inc. gross profit margin ratio deteriorated from Q2 2024 to Q3 2024 but then slightly improved from Q3 2024 to Q4 2024. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Amgen Inc. operating profit margin ratio deteriorated from Q2 2024 to Q3 2024 but then improved from Q3 2024 to Q4 2024 exceeding Q2 2024 level. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Amgen Inc. net profit margin ratio improved from Q2 2024 to Q3 2024 but then slightly deteriorated from Q3 2024 to Q4 2024. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Amgen Inc. ROE improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Amgen Inc. ROA improved from Q2 2024 to Q3 2024 but then slightly deteriorated from Q3 2024 to Q4 2024. |
Gross Profit Margin
Amgen Inc., gross profit margin calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Gross profit from product sales | 5,604) | 4,841) | 4,805) | 3,918) | 4,721) | 4,742) | 4,870) | 4,126) | 4,805) | 4,649) | 4,771) | 4,170) | 4,553) | 4,711) | 4,477) | 4,102) | 4,737) | 4,543) | 4,420) | 4,381) | ||||||
| Product sales | 8,716) | 8,151) | 8,041) | 7,118) | 7,833) | 6,548) | 6,683) | 5,846) | 6,552) | 6,237) | 6,281) | 5,731) | 6,271) | 6,320) | 6,114) | 5,592) | 6,334) | 6,104) | 5,908) | 5,894) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Gross profit margin1 | 59.85% | 58.71% | 61.56% | 64.76% | 68.60% | 72.35% | 72.87% | 73.65% | 74.17% | 73.99% | 74.00% | 73.30% | 73.44% | 74.00% | 73.97% | 74.37% | 74.59% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 69.99% | 67.21% | 62.75% | 62.28% | 62.42% | 65.76% | 68.91% | 69.43% | 70.00% | 69.62% | 70.48% | 69.53% | 68.96% | 67.72% | 65.62% | 64.82% | 66.41% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | 71.08% | 74.91% | 75.38% | 75.71% | 76.24% | 76.54% | 77.01% | 77.68% | 78.04% | 78.82% | 79.13% | 79.62% | 78.57% | 76.92% | 75.88% | 74.42% | 72.31% | — | — | — | ||||||
| Danaher Corp. | 59.50% | 59.37% | 59.27% | 58.39% | 58.74% | 58.77% | 59.17% | 60.22% | 60.21% | 60.65% | 60.77% | 60.77% | 60.95% | 60.44% | 59.24% | 57.60% | 55.98% | — | — | — | ||||||
| Eli Lilly & Co. | 81.31% | 80.91% | 80.75% | 80.16% | 79.25% | 78.67% | 77.77% | 77.67% | 76.77% | 75.61% | 75.98% | 74.40% | 74.18% | 74.85% | 74.27% | 75.88% | 77.66% | — | — | — | ||||||
| Gilead Sciences Inc. | 78.15% | 75.98% | 75.56% | 75.62% | 75.87% | 78.66% | 79.27% | 78.94% | 79.03% | 74.31% | 75.30% | 75.50% | 75.56% | 80.23% | 79.90% | 80.32% | 81.23% | — | — | — | ||||||
| Johnson & Johnson | 69.07% | 69.05% | 69.06% | 69.20% | 68.82% | 68.54% | 68.06% | 67.34% | 67.26% | 67.43% | 67.86% | 67.97% | 68.16% | 67.51% | 67.00% | 66.24% | 65.58% | — | — | — | ||||||
| Merck & Co. Inc. | 76.32% | 75.82% | 75.25% | 74.37% | 73.17% | 72.86% | 72.96% | 72.43% | 70.63% | 70.49% | 70.41% | 70.72% | 72.02% | 67.95% | 67.48% | 66.99% | 67.74% | — | — | — | ||||||
| Pfizer Inc. | 71.94% | 67.73% | 58.18% | 58.09% | 58.10% | 60.97% | 69.61% | 68.61% | 65.77% | 65.53% | 62.18% | 60.35% | 62.08% | 65.28% | 70.96% | 76.46% | 79.26% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 86.13% | 86.12% | 86.16% | 86.32% | 86.16% | 85.96% | 86.42% | 86.96% | 87.18% | 85.39% | 84.97% | 84.65% | 84.83% | 86.65% | 86.85% | 86.84% | 86.82% | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | 41.28% | 40.77% | 40.76% | 40.40% | 39.90% | 39.87% | 39.75% | 40.28% | 42.24% | 44.42% | 46.63% | 48.37% | 50.08% | 51.05% | 51.29% | 51.47% | 49.67% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 86.11% | 86.12% | 86.45% | 86.86% | 87.21% | 87.80% | 87.92% | 88.04% | 87.90% | 88.00% | 88.13% | 87.95% | 88.06% | 87.94% | 87.89% | 88.06% | 88.14% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Gross profit margin = 100
× (Gross profit from product salesQ4 2024
+ Gross profit from product salesQ3 2024
+ Gross profit from product salesQ2 2024
+ Gross profit from product salesQ1 2024)
÷ (Product salesQ4 2024
+ Product salesQ3 2024
+ Product salesQ2 2024
+ Product salesQ1 2024)
= 100 × (5,604 + 4,841 + 4,805 + 3,918)
÷ (8,716 + 8,151 + 8,041 + 7,118)
= 59.85%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Amgen Inc. gross profit margin ratio deteriorated from Q2 2024 to Q3 2024 but then slightly improved from Q3 2024 to Q4 2024. |
Operating Profit Margin
Amgen Inc., operating profit margin calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Operating income | 2,311) | 2,047) | 1,909) | 991) | 1,271) | 2,021) | 2,684) | 1,921) | 2,230) | 2,660) | 2,176) | 2,500) | 2,304) | 2,378) | 828) | 2,129) | 2,008) | 2,453) | 2,323) | 2,355) | ||||||
| Product sales | 8,716) | 8,151) | 8,041) | 7,118) | 7,833) | 6,548) | 6,683) | 5,846) | 6,552) | 6,237) | 6,281) | 5,731) | 6,271) | 6,320) | 6,114) | 5,592) | 6,334) | 6,104) | 5,908) | 5,894) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Operating profit margin1 | 22.66% | 19.97% | 20.96% | 24.72% | 29.35% | 34.55% | 37.50% | 36.07% | 38.57% | 39.31% | 38.04% | 32.78% | 31.44% | 30.14% | 30.72% | 37.23% | 37.70% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 16.22% | 24.89% | 22.31% | 23.50% | 23.49% | 27.32% | 31.03% | 28.49% | 31.21% | 30.59% | 30.33% | 32.68% | 31.89% | 30.09% | 28.95% | 23.63% | 24.81% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | -15.50% | -14.05% | -14.39% | -14.30% | 16.18% | 16.96% | 17.29% | 18.13% | 17.96% | 19.04% | 18.19% | 16.79% | 15.91% | -15.73% | -17.02% | -19.19% | -21.60% | — | — | — | ||||||
| Danaher Corp. | 20.37% | 20.11% | 21.22% | 21.05% | 21.77% | 23.83% | 25.06% | 27.02% | 27.61% | 27.35% | 25.44% | 25.23% | 25.35% | 24.63% | 25.04% | 22.30% | 18.99% | — | — | — | ||||||
| Eli Lilly & Co. | 28.64% | 24.81% | 23.28% | 20.80% | 18.92% | 18.42% | 24.17% | 22.45% | 24.97% | 24.65% | 25.50% | 25.94% | 22.45% | 23.17% | 21.81% | 22.06% | 24.69% | — | — | — | ||||||
| Gilead Sciences Inc. | 5.81% | 2.92% | 9.26% | 5.79% | 28.24% | 30.37% | 31.18% | 33.03% | 27.17% | 22.39% | 25.78% | 26.56% | 36.72% | 42.79% | 37.20% | 18.07% | 16.72% | — | — | — | ||||||
| Johnson & Johnson | 23.42% | 24.42% | 25.31% | 25.04% | 24.90% | 25.55% | 25.61% | 25.21% | 24.63% | 23.89% | 23.47% | 23.76% | 24.95% | 24.69% | 25.23% | 24.10% | 23.60% | — | — | — | ||||||
| Merck & Co. Inc. | 31.03% | 21.60% | 24.75% | 6.93% | 3.92% | 13.08% | 10.34% | 27.85% | 30.27% | 30.66% | 33.04% | 28.85% | 25.74% | 14.07% | 10.64% | 14.02% | 16.47% | — | — | — | ||||||
| Pfizer Inc. | 19.51% | 9.56% | -4.19% | -2.08% | 2.15% | 14.36% | 28.13% | 34.44% | 34.83% | 33.59% | 30.37% | 26.12% | 23.91% | 24.67% | 24.12% | 21.20% | 19.47% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 28.10% | 28.69% | 28.95% | 29.40% | 30.85% | 32.23% | 34.20% | 35.79% | 38.93% | 45.45% | 48.19% | 55.08% | 55.67% | 55.19% | 53.94% | 43.37% | 42.09% | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | 17.11% | 16.93% | 17.01% | 16.38% | 16.00% | 15.81% | 15.42% | 16.29% | 18.69% | 20.54% | 22.51% | 23.83% | 25.57% | 27.04% | 28.00% | 27.68% | 24.19% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | -2.11% | -2.54% | -3.37% | 41.16% | 38.83% | 40.16% | 41.72% | 43.93% | 48.23% | 47.72% | 48.85% | 36.93% | 36.73% | 37.17% | 33.93% | 47.14% | 46.03% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Operating profit margin = 100
× (Operating incomeQ4 2024
+ Operating incomeQ3 2024
+ Operating incomeQ2 2024
+ Operating incomeQ1 2024)
÷ (Product salesQ4 2024
+ Product salesQ3 2024
+ Product salesQ2 2024
+ Product salesQ1 2024)
= 100 × (2,311 + 2,047 + 1,909 + 991)
÷ (8,716 + 8,151 + 8,041 + 7,118)
= 22.66%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Amgen Inc. operating profit margin ratio deteriorated from Q2 2024 to Q3 2024 but then improved from Q3 2024 to Q4 2024 exceeding Q2 2024 level. |
Net Profit Margin
Amgen Inc., net profit margin calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net income (loss) | 627) | 2,830) | 746) | (113) | 767) | 1,730) | 1,379) | 2,841) | 1,616) | 2,143) | 1,317) | 1,476) | 1,899) | 1,884) | 464) | 1,646) | 1,615) | 2,021) | 1,803) | 1,825) | ||||||
| Product sales | 8,716) | 8,151) | 8,041) | 7,118) | 7,833) | 6,548) | 6,683) | 5,846) | 6,552) | 6,237) | 6,281) | 5,731) | 6,271) | 6,320) | 6,114) | 5,592) | 6,334) | 6,104) | 5,908) | 5,894) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Net profit margin1 | 12.77% | 13.58% | 10.60% | 13.35% | 24.96% | 29.52% | 31.52% | 31.77% | 26.42% | 27.88% | 26.73% | 23.42% | 24.25% | 23.03% | 23.80% | 29.60% | 29.97% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 7.59% | 9.22% | 9.71% | 11.02% | 8.95% | 11.81% | 15.50% | 13.37% | 20.39% | 23.19% | 22.04% | 22.00% | 20.54% | 13.66% | 12.40% | 10.28% | 10.08% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | -18.53% | -15.30% | -14.06% | -13.50% | 17.83% | 18.44% | 17.62% | 15.95% | 13.71% | 14.29% | 14.04% | 13.31% | 15.08% | -11.89% | -11.44% | -14.53% | -21.20% | — | — | — | ||||||
| Danaher Corp. | 16.33% | 16.39% | 17.83% | 18.54% | 19.94% | 22.89% | 22.80% | 23.32% | 22.91% | 21.65% | 20.61% | 21.32% | 21.84% | 20.97% | 21.00% | 19.17% | 16.36% | — | — | — | ||||||
| Eli Lilly & Co. | 23.51% | 20.48% | 18.86% | 17.08% | 15.36% | 15.55% | 22.01% | 20.54% | 21.88% | 20.63% | 19.58% | 20.90% | 19.71% | 21.52% | 22.71% | 23.91% | 25.24% | — | — | — | ||||||
| Gilead Sciences Inc. | 1.68% | 0.45% | 3.82% | 1.78% | 21.03% | 21.60% | 20.18% | 20.87% | 17.02% | 12.44% | 15.22% | 16.60% | 23.05% | 27.21% | 19.62% | 1.19% | 0.51% | — | — | — | ||||||
| Johnson & Johnson | 15.84% | 16.74% | 43.91% | 44.92% | 41.28% | 39.58% | 14.52% | 13.77% | 18.90% | 19.95% | 19.21% | 20.90% | 22.26% | 19.55% | 19.92% | 17.95% | 17.82% | — | — | — | ||||||
| Merck & Co. Inc. | 26.68% | 19.23% | 21.98% | 3.76% | 0.61% | 7.77% | 5.34% | 22.52% | 24.49% | 25.88% | 29.00% | 26.27% | 26.79% | 15.09% | 11.83% | 15.09% | 14.72% | — | — | — | ||||||
| Pfizer Inc. | 12.62% | 7.04% | -4.62% | -0.55% | 3.56% | 15.13% | 27.38% | 31.19% | 31.27% | 29.81% | 28.94% | 27.01% | 27.04% | 28.77% | 23.86% | 24.03% | 22.95% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 31.07% | 33.61% | 32.04% | 29.45% | 30.14% | 30.47% | 33.93% | 33.81% | 35.64% | 39.17% | 39.97% | 48.06% | 50.25% | 51.65% | 50.11% | 43.53% | 41.35% | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | 14.77% | 14.48% | 14.69% | 14.20% | 13.99% | 13.68% | 13.14% | 13.75% | 15.47% | 15.92% | 17.37% | 18.49% | 19.70% | 21.93% | 22.47% | 22.08% | 19.79% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | -4.86% | -4.52% | -4.74% | 39.46% | 36.68% | 35.94% | 35.40% | 35.40% | 37.20% | 37.62% | 38.26% | 30.84% | 30.92% | 30.52% | 29.80% | 43.06% | 43.70% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Net profit margin = 100
× (Net income (loss)Q4 2024
+ Net income (loss)Q3 2024
+ Net income (loss)Q2 2024
+ Net income (loss)Q1 2024)
÷ (Product salesQ4 2024
+ Product salesQ3 2024
+ Product salesQ2 2024
+ Product salesQ1 2024)
= 100 × (627 + 2,830 + 746 + -113)
÷ (8,716 + 8,151 + 8,041 + 7,118)
= 12.77%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Amgen Inc. net profit margin ratio improved from Q2 2024 to Q3 2024 but then slightly deteriorated from Q3 2024 to Q4 2024. |
Return on Equity (ROE)
Amgen Inc., ROE calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net income (loss) | 627) | 2,830) | 746) | (113) | 767) | 1,730) | 1,379) | 2,841) | 1,616) | 2,143) | 1,317) | 1,476) | 1,899) | 1,884) | 464) | 1,646) | 1,615) | 2,021) | 1,803) | 1,825) | ||||||
| Stockholders’ equity | 5,877) | 7,527) | 5,925) | 5,022) | 6,232) | 7,656) | 6,781) | 5,348) | 3,661) | 3,653) | 2,419) | 916) | 6,700) | 8,217) | 8,247) | 9,334) | 9,409) | 10,959) | 10,659) | 9,485) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROE1 | 69.59% | 56.20% | 52.83% | 74.93% | 107.78% | 98.82% | 117.67% | 148.04% | 178.97% | 187.11% | 271.85% | 624.78% | 87.96% | 68.26% | 69.67% | 75.91% | 77.20% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 128.66% | 84.91% | 78.77% | 74.85% | 46.94% | 53.86% | 67.50% | 57.14% | 68.60% | 83.83% | 86.24% | 76.64% | 74.91% | 55.60% | 53.01% | 37.63% | 35.30% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | -54.78% | -42.34% | -38.44% | -37.28% | 27.27% | 28.57% | 24.91% | 22.97% | 20.37% | 20.44% | 20.30% | 19.79% | 19.46% | -14.52% | -13.80% | -16.54% | -23.84% | — | — | — | ||||||
| Danaher Corp. | 7.87% | 7.59% | 8.42% | 8.24% | 8.91% | 11.29% | 12.30% | 13.47% | 14.39% | 14.40% | 13.63% | 13.93% | 14.24% | 13.54% | 13.12% | 11.76% | 9.17% | — | — | — | ||||||
| Eli Lilly & Co. | 74.62% | 58.78% | 54.14% | 47.91% | 48.65% | 44.46% | 58.73% | 50.82% | 58.64% | 59.91% | 66.61% | 65.69% | 62.16% | 76.99% | 94.20% | 88.31% | 109.79% | — | — | — | ||||||
| Gilead Sciences Inc. | 2.48% | 0.69% | 5.77% | 2.77% | 24.81% | 26.33% | 25.92% | 26.59% | 21.62% | 15.82% | 20.44% | 22.66% | 29.55% | 34.44% | 26.20% | 1.59% | 0.68% | — | — | — | ||||||
| Johnson & Johnson | 19.68% | 20.93% | 53.14% | 54.95% | 51.11% | 48.61% | 17.37% | 17.95% | 23.36% | 25.68% | 24.05% | 26.54% | 28.20% | 25.44% | 25.53% | 22.96% | 23.25% | — | — | — | ||||||
| Merck & Co. Inc. | 36.96% | 27.30% | 31.52% | 5.71% | 0.97% | 11.17% | 8.04% | 27.82% | 31.57% | 34.32% | 38.34% | 34.68% | 34.17% | 20.10% | 16.73% | 26.08% | 27.91% | — | — | — | ||||||
| Pfizer Inc. | 9.11% | 4.61% | -2.96% | -0.33% | 2.38% | 10.81% | 21.68% | 28.77% | 32.79% | 32.14% | 33.61% | 30.29% | 28.47% | 26.28% | 18.86% | 16.23% | 15.21% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 15.03% | 15.87% | 15.32% | 14.29% | 15.22% | 16.03% | 17.90% | 17.80% | 19.14% | 25.05% | 27.49% | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | 31.86% | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | 12.78% | 12.52% | 13.12% | 13.26% | 12.83% | 13.11% | 13.08% | 14.26% | 15.80% | 16.15% | 17.59% | 18.56% | 18.94% | 22.13% | 23.32% | 22.60% | 18.47% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | -3.26% | -3.07% | -3.32% | 21.67% | 20.59% | 21.01% | 21.75% | 22.59% | 23.88% | 25.12% | 26.77% | 22.47% | 23.19% | 22.83% | 21.66% | 30.76% | 31.22% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
ROE = 100
× (Net income (loss)Q4 2024
+ Net income (loss)Q3 2024
+ Net income (loss)Q2 2024
+ Net income (loss)Q1 2024)
÷ Stockholders’ equity
= 100 × (627 + 2,830 + 746 + -113)
÷ 5,877 = 69.59%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Amgen Inc. ROE improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Return on Assets (ROA)
Amgen Inc., ROA calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
| Net income (loss) | 627) | 2,830) | 746) | (113) | 767) | 1,730) | 1,379) | 2,841) | 1,616) | 2,143) | 1,317) | 1,476) | 1,899) | 1,884) | 464) | 1,646) | 1,615) | 2,021) | 1,803) | 1,825) | ||||||
| Total assets | 91,839) | 90,883) | 90,907) | 92,980) | 97,154) | 90,534) | 90,269) | 88,720) | 65,121) | 63,700) | 59,294) | 59,196) | 61,165) | 64,993) | 59,773) | 62,539) | 62,948) | 64,637) | 65,011) | 61,669) | ||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROA1 | 4.45% | 4.65% | 3.44% | 4.05% | 6.91% | 8.36% | 8.84% | 8.92% | 10.06% | 10.73% | 11.09% | 9.67% | 9.63% | 8.63% | 9.61% | 11.33% | 11.54% | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 3.17% | 3.57% | 3.76% | 4.03% | 3.61% | 4.78% | 6.42% | 5.64% | 8.53% | 9.49% | 8.83% | 8.71% | 7.88% | 5.06% | 4.50% | 3.43% | 3.07% | — | — | — | ||||||
| Bristol-Myers Squibb Co. | -9.66% | -7.75% | -6.91% | -6.21% | 8.43% | 9.08% | 8.52% | 7.75% | 6.53% | 6.80% | 6.59% | 6.07% | 6.40% | -4.87% | -4.58% | -5.53% | -7.61% | — | — | — | ||||||
| Danaher Corp. | 5.03% | 4.83% | 5.35% | 5.28% | 5.64% | 6.74% | 7.49% | 8.15% | 8.55% | 8.35% | 7.76% | 7.74% | 7.73% | 7.13% | 7.19% | 6.30% | 4.79% | — | — | — | ||||||
| Eli Lilly & Co. | 13.45% | 11.07% | 10.22% | 9.60% | 8.19% | 8.61% | 11.85% | 10.70% | 12.62% | 12.71% | 12.09% | 13.06% | 11.44% | 12.39% | 12.70% | 13.01% | 13.28% | — | — | — | ||||||
| Gilead Sciences Inc. | 0.81% | 0.23% | 1.97% | 0.86% | 9.12% | 9.42% | 8.80% | 9.02% | 7.27% | 5.33% | 6.58% | 7.16% | 9.16% | 11.02% | 7.59% | 0.45% | 0.18% | — | — | — | ||||||
| Johnson & Johnson | 7.81% | 8.24% | 20.99% | 22.37% | 20.98% | 20.85% | 6.81% | 6.49% | 9.57% | 10.94% | 10.33% | 11.12% | 11.47% | 9.98% | 10.07% | 8.76% | 8.41% | — | — | — | ||||||
| Merck & Co. Inc. | 14.62% | 10.34% | 12.20% | 2.18% | 0.34% | 4.32% | 2.98% | 12.09% | 13.30% | 14.25% | 15.48% | 13.29% | 12.35% | 7.70% | 6.14% | 7.73% | 7.72% | — | — | — | ||||||
| Pfizer Inc. | 3.76% | 1.94% | -1.20% | -0.14% | 0.94% | 4.87% | 9.75% | 14.85% | 15.91% | 15.32% | 15.01% | 13.58% | 12.11% | 11.10% | 7.78% | 7.01% | 6.23% | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 11.69% | 12.43% | 11.98% | 11.22% | 11.95% | 12.41% | 14.02% | 13.91% | 14.85% | 19.40% | 20.90% | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | 20.47% | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | 6.51% | 6.11% | 6.32% | 6.21% | 6.07% | 6.12% | 6.08% | 6.36% | 7.15% | 7.77% | 8.21% | 8.20% | 8.12% | 11.64% | 12.70% | 12.02% | 9.23% | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | -2.38% | -2.16% | -2.43% | 16.81% | 15.92% | 15.97% | 16.54% | 17.18% | 18.30% | 19.59% | 20.50% | 17.19% | 17.44% | 17.25% | 16.30% | 22.80% | 23.07% | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
ROA = 100
× (Net income (loss)Q4 2024
+ Net income (loss)Q3 2024
+ Net income (loss)Q2 2024
+ Net income (loss)Q1 2024)
÷ Total assets
= 100 × (627 + 2,830 + 746 + -113)
÷ 91,839 = 4.45%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Amgen Inc. ROA improved from Q2 2024 to Q3 2024 but then slightly deteriorated from Q3 2024 to Q4 2024. |